• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MODV INVESTOR ALERT: Kirby McInerney LLP Notifies ModivCare, Inc. Investors of Upcoming Lead Plaintiff Deadline in Class Action Lawsuit

By: Kirby McInerney LLP via Business Wire
February 20, 2025 at 20:00 PM EST

The law firm of Kirby McInerney LLP reminds investors of the March 31, 2025, deadline to seek the role of lead plaintiff in a federal securities class action filed on behalf of investors who acquired ModivCare, Inc. (“ModivCare” or the “Company”) (NASDAQ: MODV) securities during the period from November 3, 2022, through September 15, 2024 (“the Class Period”).

[LEARN MORE ABOUT THE CLASS ACTION]

On May 4, 2023, before market hours, ModivCare issued a press release reporting its financial results for first quarter 2023. During the associated earnings call on the same day, CFO Kenneth Shepherd revealed the Company experienced a reduction of cash flow during the quarter. On this news, the price of ModivCare shares declined by $11.30 per share, or approximately 16%, from $69.30 per share on May 3, 2023, to close at $58 on May 4, 2023.

On August 3, 2023, after market hours, ModivCare issued a press release reporting its financial results for second quarter 2023. During the associated earnings call on the same day, CEO Heath Sampson informed investors the Company experienced the expansion of a “large payable balance” that impacted the Company’s cash flow from operations during the quarter. On this news, the price of ModivCare shares declined by $2.86, from $38.24 per share on August 4, 2023.

Then, on February 23, 2024, before market hours, ModivCare issued a press release reporting its financial results for fourth quarter 2023. During the associated earnings call, Sampson informed investors that the Company had suffered negative cash flow during the quarter and expected the trend to continue for the first half of fiscal year 2024. On this news, the price of ModivCare shares declined by $17.25, or nearly 39%, from $43.87 per share on February 22, 2024, to close at $26.62 per share on February 23, 2024.

Thereafter, on September 12, 2024, before market hours, the Company issued a press release reporting, among other things, that it would “undertake actions to seek additional capital, including filing a shelf registration statement” with the SEC to improve its liquidity. On this news, the price of ModivCare shares declined by $18.43, or approximately 59%, from $31.19 per share on September 11, 2024, to close at $12.76 per share on September 12, 2024.

Finally, on September 16, 2024, before market hours, ModivCare issued a press released titled “ModivCare Provides Financial Update.” Therein, the Company revised its 2024 Adjusted EBITDA guidance range from $185-$195 million to $170-$180 million, “primarily due to [non-emergency medical transportation] NEMT segment pricing accommodations made to strategically retain and expand key customer relationships.” On this news, the price of ModivCare shares declined by $1.40, from $14.12 per share on September 15, 2024, to close at $12.72 per share on September 16, 2024.

The complaint alleges that defendants, throughout the Class Period, failed to disclose that certain contracts used in ModivCare’s NEMT segment caused the Company’s free cash flow to deteriorate and that, as a result, (1) contract renegotiations and pricing accommodations negatively impacted the Company’s adjusted EBITDA; and (2) the Company had insufficient liquidity.

If you purchased or otherwise acquired ModivCare securities, have information, or would like to learn more about this investigation, please contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the form below, to discuss your rights or interests with respect to these matters without any cost to you.

[CONTACT FORM]

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250220061117/en/

Contacts

Kirby McInerney LLP

Thomas W. Elrod, Esq.

212-699-1180

https://www.kmllp.com

investigations@kmllp.com

More News

View More
Will Hims & Hers Fall Along With Novo Nordisk?
Today 17:07 EDT
Via MarketBeat
Tickers HIMS NVO
Play It Cool: Why Comfort Systems USA Is a Hidden AI Winner
Today 15:21 EDT
Via MarketBeat
Topics Artificial Intelligence
Tickers FIX META MSFT NVDA
Rocket Lab Reports Next Week: Here’s What Investors Should Know
Today 10:49 EDT
Via MarketBeat
Tickers RKLB
Apple Stock: Big Earnings, Small Move—Time to Buy?
Today 9:25 EDT
Via MarketBeat
Tickers AAPL META MSFT
Amazon's Earnings: What Comes Next and How to Play It
Today 9:10 EDT
Via MarketBeat
Tickers AMZN
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap